Ms. Vanessa Slowey reports

TELYRX ANNOUNCES YEAR-END 2025 FINANCIAL RESULTS

Telyrx Holdings Inc. today filed audited financial statements for Telyrx Inc., its wholly owned subsidiary and reverse takeover acquirer, on SEDAR+ for the year ended Dec. 31, 2025. All dollar amounts are expressed in U.S. dollars.

Highlights for the year and fourth quarter of 2025:

• Revenue increased to $42.9-million for the year ended Dec. 31, 2025, compared with $9.5-million for the period ended Dec. 31, 2024, and increased to $14.3-million in the fourth quarter of 2025, compared with $12.3-million in the third quarter of 2025 and $4.6-million in the fourth quarter of 2024;
• Number of prescriptions filled increased to 177,713 in the fourth quarter of 2025, compared with 149,857 in the third quarter of 2025 and 53,390 in the fourth quarter of 2024;
• First quarter 2026 results with full financials to be released in May, 2026.

"Our record fourth quarter and year-end 2025 revenue is further testament to the fact that Americans are choosing a better way to access their prescriptions," said Vanessa Slowey, chief executive officer of Telyrx. "We have grown revenues consistently quarter over quarter. We are doing it by giving people the choice, flexibility and convenience that the traditional pharmacy and insurance models simply don't offer, all within one of the fastest-growing segments of the U.S. health care market."

The cash-pay prescription market is the fastest-growing segment of the approximately $806-billion prescription drug market. Telyrx's vertically integrated business model delivers essential medication directly to consumers with less time, cost and complexity.

About Telyrx Holdings Inc.

Telyrx is a technology-enabled health care and pharmacy services company operating a digital pharmacy platform connecting patients with independent, state-licensed providers to access over 400 everyday medications across 48 U.S. states and territories. The company fulfills prescriptions through its licensed retail pharmacies and offers fast, convenient delivery of medications directly to patients' doors.

We seek Safe Harbor.